Effectiveness of Inhaled Combined Corticosteroid/Long-Acting Bronchodilator Treatment in Reducing COPD Exacerbations and Short-Acting Bronchodilator Use
نویسنده
چکیده
• Objective: To compare budesonide/formoterol (BFC) and fluticasone propionate/salmeterol (FSC) in their ability to reduce COPD exacerbations using a novel risk stratification approach. • Design: Retrospective cohort study with propensity matching and stratification by short-acting beta2-agonist (SABA) use. • Participants: 7704 COPD patients identified using 2 U.S. health claims databases (study period: 1/1/2004
منابع مشابه
Medications for COPD: a review of effectiveness.
Chronic obstructive pulmonary disease (COPD) is a common problem among patients presenting to primary care. This condition has multiple individual and combined treatment regimens. The goals of treatment are to improve quality of life, exercise tolerance, sleep quality, and survival; and to reduce dyspnea, nocturnal symptoms, exacerbations, use of rescue medications, and hospitalizations. All pa...
متن کاملTriple therapy for the management of COPD: a review.
Triple therapy for COPD consists of a long-acting anti-cholinergic bronchodilator, a long-acting beta-agonist bronchodilator, and an inhaled corticosteroid. Guidelines from the Canadian Thoracic Society advocate triple therapy for some patients with moderate-to-severe COPD. The objective of this review was to evaluate the evidence based clinical efficacy of triple therapy compared to dual bronc...
متن کاملWhen is dual bronchodilation indicated in COPD?
Inhaled bronchodilator medications are central to the management of COPD and are frequently given on a regular basis to prevent or reduce symptoms. While short-acting bronchodilators are a treatment option for people with relatively few COPD symptoms and at low risk of exacerbations, for the majority of patients with significant breathlessness at the time of diagnosis, long-acting bronchodilato...
متن کاملThe role of tiotropium in the hospital management of exacerbation of chronic obstructive pulmonary disease.
According to current guidelines regarding the hospital management of exacerbations of chronic obstructive pulmonary disease (COPD), short-acting inhaled 2 agonists are generally the preferred bronchodilators (evidence grade A).1 In the absence of a prompt response to those drugs, addition of a short-acting anticholinergic bronchodilator is recommended, although the effectiveness of this combina...
متن کاملAssessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD.
The long-acting inhaled bronchodilators available for use in chronic obstructive pulmonary disease (COPD) vary in their pharmacological class (β2-adrenergic agonist or antimuscarinic/anticholinergic, alone or combined), durations of action and speed of onset of bronchodilator effect. In the early stages of development of a maintenance bronchodilator, the goals are to identify a molecule with th...
متن کامل